Viventia Bio

General Information

We are a biologics oncology company focused on designing, engineering and developing targeted protein therapeutics, or TPTs. Our most advanced product candidate is Vicinium, which is a locally-administered TPT. In the third quarter of 2015, we commenced in the United States and Canada a Phase 3 clinical trial of Vicinium for the treatment of subjects with high-grade non-muscle invasive bladder cancer, or NMIBC, who have previously failed two treatments of Bacillus Calmette-Guérin, or BCG. Our second most advanced product candidate is Proxinium, a locally administered TPT intended for the treatment of squamous cell carcinoma of the head and neck, or SCCHN.

Employees: 26
Founded: 2012
Contact Information
Address 147 Hamelin Street, Winnipeg, MB R3T 3Z1, Canada
Phone Number 204-478-1023
Web Address
View Prospectus: Viventia Bio
Financial Information
Market Cap
Revenues $0 mil (last 12 months)
Net Income $-9.8 mil (last 12 months)
IPO Profile
Symbol VITA
Exchange NASDAQ
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $86.3 mil
Manager / Joint Managers Leerink Partners/ Cowen and Company/ Guggenheim Securities
CO-Managers -
Expected To Trade:
Status: Withdrawn
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change